Impact of continuous flow left ventricular assist device therapy on chronic kidney disease: a longitudinal multicenter study

Left ventricular assist devices (LVADs) have become an accepted treatment modality for end-stage heart failure (HF) patients.(1) End-stage HF patients often suffer from end-organ dysfunction, including chronic kidney disease (CKD), which is often attributed to the cardio-renal syndrome.(2) Cardio-renal syndrome type 2, renal dysfunction caused by a number of factors including high central venous pressures and insufficient cardiac output, frequently hampers the quality of life of these patients.(3) They are at risks for developing end-stage renal disease and have higher rates of mortality following LVAD implantation.(4 –6)

Source: Journal of Cardiac Failure - January 21, 2020 Category: Cardiology Authors: Yunus C. Yalcin, Rahatullah Muslem, Kevin M. Veen, OsamaI. Soliman, Dennis A. Hesselink, Alina A. Constantinescu, Jasper J. Brugts, Olivier C. Manintveld, Marat Fudim, Stuart D Russell, Brett Tomashitis, Brian A. Houston, Steven Hsu, Ryan J. Tedford, AdJ. Source Type: research